These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15811174)

  • 1. Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.
    Ozaki H; Ishikawa CT; Ishii T; Toyoda A; Murano T; Miyashita Y; Shirai K
    J Clin Pharm Ther; 2005 Apr; 30(2):189-92. PubMed ID: 15811174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis.
    Kaspera R; Naraharisetti SB; Tamraz B; Sahele T; Cheesman MJ; Kwok PY; Marciante K; Heckbert SR; Psaty BM; Totah RA
    Pharmacogenet Genomics; 2010 Oct; 20(10):619-29. PubMed ID: 20739906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin.
    Ishikawa C; Ozaki H; Nakajima T; Ishii T; Kanai S; Anjo S; Shirai K; Inoue I
    J Hum Genet; 2004; 49(10):582-585. PubMed ID: 15365880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel.
    Floyd JS; Kaspera R; Marciante KD; Weiss NS; Heckbert SR; Lumley T; Wiggins KL; Tamraz B; Kwok PY; Totah RA; Psaty BM
    Clin Pharmacol Ther; 2012 May; 91(5):896-904. PubMed ID: 22419147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerivastatin, genetic variants, and the risk of rhabdomyolysis.
    Marciante KD; Durda JP; Heckbert SR; Lumley T; Rice K; McKnight B; Totah RA; Tamraz B; Kroetz DL; Fukushima H; Kaspera R; Bis JC; Glazer NL; Li G; Austin TR; Taylor KD; Rotter JI; Jaquish CE; Kwok PY; Tracy RP; Psaty BM
    Pharmacogenet Genomics; 2011 May; 21(5):280-8. PubMed ID: 21386754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of cerivastatin.
    Mück W
    Clin Pharmacokinet; 2000 Aug; 39(2):99-116. PubMed ID: 10976657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.
    Nakajima M; Fujiki Y; Kyo S; Kanaya T; Nakamura M; Maida Y; Tanaka M; Inoue M; Yokoi T
    J Clin Pharmacol; 2005 Jun; 45(6):674-82. PubMed ID: 15901749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerivastatin and gemfibrozil-associated rhabdomyolysis.
    Bruno-Joyce J; Dugas JM; MacCausland OE
    Ann Pharmacother; 2001 Sep; 35(9):1016-9. PubMed ID: 11573847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.
    Shitara Y; Hirano M; Sato H; Sugiyama Y
    J Pharmacol Exp Ther; 2004 Oct; 311(1):228-36. PubMed ID: 15194707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemfibrozil greatly increases plasma concentrations of cerivastatin.
    Backman JT; Kyrklund C; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2002 Dec; 72(6):685-91. PubMed ID: 12496749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myoglobin clearance as an early indicator for rhabdomyolysis-induced acute renal failure.
    Laios ID; Caruk R; Wu AH
    Ann Clin Lab Sci; 1995; 25(2):179-84. PubMed ID: 7785966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors].
    Sparing R; Sellhaus B; Noth J; Block F
    Nervenarzt; 2003 Feb; 74(2):167-71. PubMed ID: 12596018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Massive rhabdomyolysis associated with the use of cerivastatin monotherapy].
    Vera M; Pou M; Botey A; Cases A
    Nefrologia; 2001; 21(6):613-4. PubMed ID: 11881437
    [No Abstract]   [Full Text] [Related]  

  • 14. [Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination].
    Sirvent AE; Cabezuelo JB; Enríquez R; Amorós F; González C; Reyes A
    Nefrologia; 2001; 21(5):497-500. PubMed ID: 11795020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
    Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
    Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
    Kajosaari LI; Jaakkola T; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2006 Mar; 62(3):217-23. PubMed ID: 16447051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Another report of acute rhabdomyolysis following cerivastatin monotherapy.
    Milionis HJ; Tsapoga TG; Elisaf MS
    Arch Intern Med; 2001 Nov; 161(21):2629-30. PubMed ID: 11718615
    [No Abstract]   [Full Text] [Related]  

  • 18. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
    Kajosaari LI; Niemi M; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2006 Mar; 79(3):231-42. PubMed ID: 16513447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversy surrounding the safety of cerivastatin.
    Davidson MH
    Expert Opin Drug Saf; 2002 Sep; 1(3):207-12. PubMed ID: 12904136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone and severe cerivastatin-induced rhabdomyolysis.
    Giner V; Muñoz R; Redón J
    J Intern Med; 2002 Feb; 251(2):177-8. PubMed ID: 11905593
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.